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374Identiﬁcation of a potential proinﬂammatory
genetic proﬁle inﬂuencing carotid plaque
vulnerability
FedericoBiscetti,MD,PhD,a,bGiuseppeStraface,MD,cGiovanniBertoletti,MD,dClaudioVincenzoni,MD,e
Francesco Snider, MD,e Vincenzo Arena, MD,f Raffaele Landolﬁ, MD,a and Andrea Flex, MD,a,b Rome and
Latina, Italy
Objective: Atherosclerosis and vascular remodeling after injury are driven by inﬂammation and mononuclear cell inﬁl-
tration. Unstable atherosclerotic plaques are characterized by a large necrotic core. In this study we investigated the
distribution and interaction between gene polymorphisms encoding proinﬂammatory molecules in an Italian population
with internal carotid artery stenosis (ICAS). We also evaluated whether reciprocal interaction between these gene poly-
morphisms increased the risk of plaque vulnerability.
Methods: In this genetic association study, 11 proinﬂammatory gene polymorphisms were analyzed in 933 individuals
comprising 344 patients with ICAS who underwent carotid endarterectomy and 589 controls without ultrasound evi-
dence of atherosclerosis or intimal thickening.
Results: We found that interleukin (IL) 6 (IL-6), IL-1b, monocyte chemoattractant protein-1 (CCL2) macrophage
inﬂammatory protein-1a (CCL3), E-selectin (SELE), intercellular adhesion molecule 1 (ICAM1), and matrix
metalloproteinase-3 (MMP-3), and 9 (MMP-9) gene variants were independently and signiﬁcantly associated with ICAS.
The association remained signiﬁcant even after the Bonferroni correction. We also found a genetic proﬁle associated with
different risks for ICAS, depending on the number of high-risk genotypes simultaneously present in an individual.
Furthermore, proinﬂammatory genetic proﬁles are signiﬁcantly more common in individuals with unstable carotid
plaque.
Conclusions: Our study shows, for the ﬁrst time, a reciprocal interaction between proinﬂammatory genotypes for the
development and progression of ICAS. (J Vasc Surg 2015;61:374-81.)Ischemic stroke is the second cause of death worldwide.
That carotid atherosclerosis highly predisposes to cerebral
ischemic events is well established, and mounting evidence
correlates carotid plaque texture with its stability.1 Other
risk factors may be important in the development of athero-
sclerosis in addition to known cardiovascular risk factors,
such as diabetes and hypertension,2 although themechanism
in the formation and progression of plaque is not completely
understood.
The essential process in the major cardiovascular dis-
eases, such as coronary artery disease,3 peripheral arterial dis-
ease, and stroke, is the rupture of atherosclerotic plaque.4
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://dx.doi.org/10.1016/j.jvs.2014.08.113response, and several biomarkers (cytokine, markers of pla-
que destabilization, and plaque rupture) are increased in pa-
tients with major cardiovascular events.5 Several studies
show that these proinﬂammatory molecules are play an
important role in development of the atherosclerosis and in
atherosclerotic diseases: high C-reactive protein (CRP)
levels have been correlated with plaque vulnerability,6 inter-
leukin (IL)-6 is increased in the shoulder region and is very
important in plaque destabilization,7,8 and higher matrix
metalloproteinase (MMP) concentrations are involved in
unstable plaque through an upregulation of the monocyte
chemotactic protein-1/C-C chemokine receptor type
2 pathway.9,10
Importantly, single nucleotide polymorphisms (SNPs)
located in functional regions of the genemay inﬂuence serum
concentrations and functional activities of proteins and
contribute to clinical complications.11 On the other hand,
neither proinﬂammatory biomarkers nor any one gene poly-
morphism, taken individually, showed evidence to predict in-
dividual risk. No attempt has been made to better investigate
whether these factors, taken together, deﬁne sufﬁcient risk sets
for carotid atherosclerosis or carotid plaque stability. Several
studies suggested that reciprocal interaction between gene
variants increased the risk to develop type 1 diabetes,12 atro-
phic gastritis,13 ischemic stroke,14 and rheumatoid arthritis.15
This study analyzed, in an Italian population, the
distribution and frequency of 11 proinﬂammatory gene poly-
morphisms: IL-6 (-174G/C [rs1800795]), IL-1b (-31 T/C
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-2518A/G[rs1024611]),macrophage inﬂammatoryprotein
1a (CCL3; -906 T/A [rs6075]), E-selectin (SELE; Ser128-
Arg [rs5361]), intercellular adhesion molecule-1 (ICAM-1;
469 E/K [rs5498]), MMP-3 (-1171 5A/6A [rs679620]),
MMP-9 (-1562 C/T [rs3918242]), CRP (1059 G/C
[rs1800947]), macrophage migration inhibitory factor
(MIF; -173 G/C [rs755622]), and tumor necrosis factor-a
(TNF-a; -308 G/A [rs1800629]). Our goal was to deﬁne
whether the presence of a synergistic effect increases the risk
for the presence and severity of internal carotid stenosis,
deﬁned as high-grade ($70%) carotid stenosis (ICAS).METHODS
Ethics statement. This study was performed in accor-
dance with the 1964 Declaration of Helsinki. The ethics
committees of the A. Gemelli University Hospital (Rome)
and St M. Goretti Hospital (Latina, Italy) approved the
study. Informed written consent was obtained from all par-
ticipants. Data were analyzed anonymously.
Study population. Westudied 344 consecutive patients
with ICAS (mean age, 72.6 6 4.7 years) who underwent
carotid endarterectomy and 589 controls (mean age,
72.7 6 5.5 years) among patients consecutively admitted to
the Department of Internal Medicine of the A. Gemelli Uni-
versity Hospital (Rome) or St M. Goretti Hospital (Latina,
Italy), from January 1, 2009, to September 15, 2013. The
control patients were matched for sex and age and were
without Doppler ultrasound evidence of atherosclerosis or
intimal thickening or clinical or radiologic evidence of cere-
brovascular disease.
Carotid endarterectomy was performed according to
established criteria.16-18 The cases and controls were not
related. All patients were from central and southern Italy,
were white, and had independent pedigrees. All patients
enrolled in the study underwent a vascular evaluation with
color-coded echo ﬂow imaging of the carotid arteries and
a resting electrocardiogram. Neurologic symptoms were
assessed by neurologic evaluation, and radiologic evidence
of cerebrovascular events was assessed by cerebral computed
tomography.
Each patient underwent a careful clinical assessment for
the major cardiovascular risk factors of hypercholesterole-
mia, hypertension, smoking, age, and diabetes mellitus.
Diabetes mellitus was determined by the presence of an
existing diagnosis, glycosylated hemoglobin Alc >5.8%, fast-
ing blood glucose >126 mg/dL, and use of antidiabetic
drugs. Patients with a systolic blood pressure >140 mm
Hg and a diastolic blood pressure >90 mm Hg or who
used antihypertensive drugs were deﬁned as hypertensive.
Patients with a total cholesterol level >200 mg/dL or
who used statins were deﬁned as hypercholesterolemic.
Patients who had stopped smoking$1 year before the study
or had never smoked were classiﬁed as nonsmokers, and all
other were classiﬁed as smokers. Patients who underwent ca-
rotid endarterectomy were previously studied by ultrasound
imaging and angiography.Study exclusion criteria were cancer (current or previ-
ous), autoimmune diseases, the use of immunosuppressive
drugs, chronic infectious or inﬂammatory diseases, and he-
matologic disorders.
Genotyping. DNAwas extracted from peripheral blood
andassayedbypolymerase chain reaction-restriction fragment
length polymorphism to detect the CRP (-1059 G/C), IL-6
(-174 G/C), IL-1b (-31 T/C), TNF-a (-308 G/A), MIF
(-173G/C),CCL2 (-2518A/G),CCL3 (-906T/A), SELE
(Ser128Arg), ICAM-1 (469E/K),MMP-3 (-11715A/6A),
andMMP-9 (-1562C/T)genepolymorphisms, as previously
reported.19-27
Histologic assays. After endarterectomy, carotid pla-
que was brieﬂy rinsed in saline solution, immersed in buff-
ered 10% formalin ﬁxative and then in formic acid (a
decalcifying solution), and subsequently sectioned. Each
plaque was sectioned transversely into 4-mm blocks, start-
ing from the plaque base and then distally until the bifurca-
tion was cut. Each block was processed in parafﬁn, cut into
4-mm sections, and the proximal end of one slice per block
was stained sequentially with hematoxylin and eosin (1%).
Fibrosis, calciﬁcation, atheroma, thrombosis, and
necrotic core were evaluated in each section. The minimum
magniﬁcation was used to evaluate the relative necrotic core,
andhighermagniﬁcationswere used to evaluate the presence
of hemorrhage and calciﬁcation. The largest plaque area,
which in some cases is the maximum stenosis area, was eval-
uated in a morphologic study. In the deeper regions was
located the necrotic core, characterized by amorphousmate-
rial and cholesterol clefts, without collagen and viable cells.
Dark blue color shows calciﬁcations and demarcated regions
devoid of cells in hematoxylin and eosin stains, whereas
degenerated red blood cells and macrophage engulfment
of hemosiderin and giant cells are typical of intraplaque
hemorrhage.
Carotid plaques were classiﬁed as stable or unstable
according to the American Heart Association criteria, as
deﬁned by Stary et al28 and modiﬁed by Virmani et al.29
According to the Stary classiﬁcation, carotid plaques types
IV, Vb, and Vc, which had a thick ﬁbrous or ﬁbrocalciﬁc
component, lined by endothelium, covering a possible cen-
tral foamy or necrotic core, were considered stable. Carotid
plaques type IV (the lesion surface contains proteoglycans
andmacrophage foam cells and only isolated smoothmuscle
cells and minimal collagen), type Va, and type VI (presence
of overt, hemorrhagic, ulcerated, or thrombotic plaques)
were considered unstable.1 Selection of stable or unstable
plaque was performed in accordance with the modiﬁed
scheme established by Virmani et al29 (Fig).
Statistical analysis. Clinical and demographic data in
the two groups were described and compared using the c2
test for categoric variables, the Fisher exact test for categoric
variables with expected low frequency in one ormore cells of
the contingency table, and by the t-test for unpaired samples
with unequal variance for continuous variables. Genotype
frequencies were compared by the c2 test. Hardy-
Weinberg equilibrium was evaluated by a c2 test or the
Fisher exact test, as appropriate. Linkage disequilibrium
Table I. Demographic and clinical data of study
participants
Variablesa
ICAS
(n ¼ 344)
Controls
(n ¼ 589) P
Age, years 72.6 6 4.7 72.7 6 5.5 .758b
Sex
Males 117 224
Females 227 365 .128c
Hypertension 216 (62.8) 325 (55.2) .021c
Hypercholesterolemia 205 (59.6) 305 (51.8) .013c
Total cholesterol level,
mg/dL
213 6 29.8 189 6 25.4 .017b
Diabetes 208 (60.5) 179 (30.4) <.01c
Body mass index, kg/m2 30.3 6 6.6 27.5 6 4.7 <.01b
Coronary artery disease 148 (43.0) 231 (39.2) .286c
History of ischemic stroke 171 (49.7) 0 (0.0) <.01c
PAOD 113 (32.8) 185 (31.4) .439c
Hs-CPR level, mg/dL 7.2 6 0.2 4.1 6 2.1 <.01b
Treatment
Statins 211 (61.3) 119 (20.2) <.01c
ACE inhibitor 185 (53.8) 295 (50.1) .432c
b-Blockers 139 (40.4) 221 (37.5) .302c
Current smoking 129 (37.5) 186 (31.6) .023c
ACE, Angiotensin converting enzyme; hs-CPR, high-sensitive C-reactive
protein; ICAS, internal carotid artery stenosis; PAOD, peripheral arterial
occlusive disease.
aContinuous data are shown as mean 6 standard deviation and categoric
data as number (%).
bStatistical test performed with the Student t-test.
cThe c2 test was used for categoric values.
Fig. Light microscopy photomicrograph shows a carotid
endarterectomy specimen of unstable plaque (USP; original
magniﬁcation100).
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(Broad Institute, Cambridge, Mass) for all pairwise SNP
combinations. Odds ratios (ORs) were calculated alongwith
95% conﬁdence intervals (CIs). A logistic regression model
was used to estimate the association between genotype and
presence of ICAS. Stata 11.0 software (StataCorp LP, Col-
lege Station, Tex) was used for all analyses. P < .05 was
established as indicating statistical signiﬁcance, and the
Bonferroni correction was used to adjust P values for mul-
tiple testing.
RESULTS
Table I reports the clinical and demographic data of pa-
tients with ICAS and control patients. Univariate correlations
found no signiﬁcant differences between the groups in age
(P ¼ .758), sex (P ¼ .128), coronary artery disease (P ¼
.286), and peripheral arterial occlusive disease (P ¼ .439).
In contrast, hypertension (P ¼ .021), hypercholesterolemia
(P ¼ .013), total cholesterol level (P ¼ .017), diabetes (P <
.01), body mass index (P < .01), history of ischemic stroke
(P< .01), high-sensitivity CRP level (P< .01), and smoking
(P ¼ .023) were signiﬁcantly more frequent in patients with
ICAS than in controls.
Table II summarizes genotype frequencies. All geno-
types were in Hardy-Weinberg equilibrium. These SNPs
are not in linkage disequilibrium. Of the 344 patients
with ICAS, the genotype distribution of the IL-6 gene
was 132 GG, 155 GC, and 57 CC, which was signiﬁcantly
different than in the 589 controls (135 GG, 272 GC, and
182 CC). The frequency of the GG genotype in ICAS
(38.4%) was signiﬁcantly higher than in control patients
(22.9%; P < .001). Similarly, the genotype distribution ofthe IL-1b gene was 43 TT, 154 CT, and 147 CC in
ICAS patients, which was signiﬁcantly different than in
control patients (58 TT, 248 CT, and 283 CC), and the
frequency of the TT genotype in ICAS (12.5%) was signif-
icantly higher than in controls (9.8%; P ¼ .006).
The genotype distribution of the CCL2 gene was
77 GG, 153 AG, and 114 AA in patients, which was signif-
icantly different from that observed in controls (50 GG,
275 AG and 264 AA). The frequency of the GG genotype
in ICAS (22.4%) was signiﬁcantly higher than in control
patients (8.5%; P < .001). Similarly, ICAS patients had
signiﬁcantly different frequencies than control patients of
the CCL3 (47.4% vs 39.0%; P < .001) SELE (5.0% vs
1.4%; P < .001), ICAM-1 (23.2% vs 11.2%; P < .001),
and MMP-3 (24.4% vs 14.4%; P < .001) polymorphisms
(Table II). The frequency of the TT genotype of the
MMP-9 gene in patients with ICAS (4.4%) was higher
than in controls (1.2%; P ¼ .008; Table II). The genotype
distribution for the CRP (P ¼ .78), MIF (P ¼ .12), and
TNF-a (P ¼ .47) polymorphisms was similar in patients
and controls.
After these observations, a logistic regression analysis,
adjusted for relevant confounding variables such as age,
sex, hypertension, hypercholesterolemia, diabetes, coro-
nary artery disease, peripheral arterial occlusive disease, his-
tory of ischemic stroke, and smoking, was used to evaluate
whether these gene variations were independent variables
associated with ICAS. We found that the GG, TT, GG,
Table III. Logistic regression analysis
Genotypes OR (95% CI)a
IL-6/GG 3.1 (1.9-4.5)
IL-1b/TT 2.0 (1.3-3.3)
CCL2/GG 3.9 (2.2-6.3)
CCL3/66 2.1 (1.4-3.1)
SELE/AA 5.1 (2.1-13.4)
ICAM-1/EE 3.7 (2.3-6.1)
MMP-3/5A5A 2.5 (1.6-3.8)
MMP-9/TT 3.9 (1.4-8.9)
CRP/CC NS
MIF/CC NS
TNF-a/AA NS
CCL2, Monocyte chemoattractant protein-1; CCL3, macrophage inﬂam-
matory protein-1a; CI, conﬁdence interval; CRP, C-reactive protein; IL,
interleukin; ICAM-1, intercellular adhesion molecule-1; MIF, macrophage
migration inhibitory factor; MMP, matrix metalloproteinase; OR, odds ra-
tio; NS, not signiﬁcant; SELE, E-selectin, ICAM-1, intercellular adhesion
molecule-1; TNF, tumor necrosis factor.
aORs adjusted for age, sex, presence of hypertension, hypercholesterolemia,
diabetes, coronary artery disease, peripheral arterial occlusive disease, history
of ischemic stroke, and smoking.
Table II. Genotype distribution in patients with internal
carotid artery stenosis (ICAS) and controls
Genotypes
ICAS (n ¼ 344),
No. (%)b
Controls (n ¼ 589),
No. (%)b Pa
IL-6
GG 132 (38.4) 135 (22.9) <.001
GC 155 (45.0) 272 (46.2)
CC 57 (16.6) 182 (30.9)
IL-1b
TT 43 (12.5) 58 (9.8) .006
CT 154 (44.8) 248 (42.1)
CC 147 (42.7) 283 (48.1)
CCL2
GG 77 (22.4) 50 (8.5) <.001
AG 153 (44.5) 275 (46.7)
AA 114 (33.1) 264 (44.8)
CCL3
66 163 (47.4) 230 (39.0) <.001
64 147 (42.7) 282 (47.9)
44 34 (9.9) 77 (13.1)
SELE
AA 17 (5.0) 8 (1.4) <.001
AS 137 (39.8) 165 (28.0)
SS 190 (55.2) 416 (70.6)
ICAM-1
EE 80 (23.2) 66 (11.2) <.001
EK 187 (54.4) 292 (49.6)
KK 77 (22.4) 231 (39.2)
MMP-3
5A5A 84 (24.4) 85 (14.4) <.001
6A5A 171 (49.7) 298 (50.6)
6A6A 89 (25.9) 206 (35.0)
MMP-9
TT 15 (4.4) 7 (1.2) .008
CT 102 (29.6) 159 (27.0)
CC 227 (66.0) 423 (71.8)
CRP
CC 12 (3.5) 19 (3.2) NS
GC 79 (23.0) 139 (23.6)
GG 253 (73.5) 431 (73.2)
MIF
CC 19 (5.5) 31 (5.3) NS
GC 109 (31.7) 188 (31.9)
GG 216 (62.8) 370 (62.8)
TNF-a
AA 18 (5.2) 26 (4.4) NS
AG 119 (34.6) 191 (32.4)
GG 207 (60.2) 372 (63.2)
CCL2, Monocyte chemoattractant protein-1; CCL3, macrophage inﬂam-
matory protein-1a; CRP, C-reactive protein; IL, interleukin; MIF, macro-
phage migration inhibitory factor; MMP, matrix metalloproteinase; NS, not
signiﬁcant; SELE, E-selectin, ICAM-1, intercellular adhesion molecule-1;
TNF, tumor necrosis factor.
aP values assessed by Fisher exact test for categoric values.
bNumbers in parentheses are percentages of total.
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CCL2, CCL3, SELE, ICAM-1, MMP-3, and MMP-9
gene polymorphisms, respectively, were independently
associated with ICAS (Table III).
Next, to evaluate whether the reciprocal interaction of
these gene variations increased the risk for ICAS, we strat-
iﬁed patients and controls according to the number of
high-risk proinﬂammatory genotypes (Table IV) andfound that the OR for ICAS increased progressively with
the number of high-risk genotypes (HRGs) carried by a
single subjects, from 1.6 (95% CI, 1.2-3.2) in the individ-
uals with two HRGs, to 2.6 (95% CI, 1.5-5.9) in patients
with three HRGs, and peaked at 6.8 (95% CI, 2.1-26.3)
in patients concomitantly carrying four HRGs. The 13 pa-
tients with ﬁve or more HRGs were affected by ICAS
(Table IV).
In the next step of our study, we grouped 344 patients
with ICAS by whether they had unstable plaque (USP; n ¼
156) or stable plaque (SP; n ¼ 188). In the 156 patients
with USP, the genotype distribution of the IL-6 gene poly-
morphisms was 80 GG, 57 GC, and 19 CC, which was
signiﬁcantly different from that observed in the 188 pa-
tients with SP (52 GG, 98 GC, and 38 CC; Table V).
The GG genotype in USP (51.3%) was signiﬁcantly higher
than in SP (27.7%; P < .001). Similarly, USP and SP had
signiﬁcantly different frequencies of the IL-1b (21.2% vs
5.3%; P < .001) CCL2 (34.6% vs 12.2%; P < .001),
CCL3 (61.5% vs 35.6%; P < .001), SELE (7.7% vs 2.7%;
P ¼ .002), and ICAM-1 (35.3% vs 13.3%; P < .001) poly-
morphisms (Table V). Likewise, the frequency of the
5A5A genotype of the MMP-3 gene was more than four
times higher in USP than in SP (41.7% vs 10.1%; P <
.001; Table V). The TT genotype of the MMP9 gene
variant appeared in 1.6% of patients with SP, whereas the
same genotype was more common in patients with USP
(7.7%; P ¼ .02).
After adjustment for the same variables, all eight SNPs
were independently associated with USP. This analysis
showed that the homozygous GG, TT, GG, 66, AA, EE,
5A5A, and TT genotypes of the IL-6, IL-1b, CCL2,
CCL3, SELE, ICAM-1, MMP-3, and MMP-9 gene vari-
ants are independent risk factors for unstable plaque; in
particular, patients carrying the GG, TT, GG, 66, AA,
Table IV. Risk for internal carotid artery stenosis (ICAS) according to the number of proinﬂammatory gene
polymorphisms
HRGs, No. Patients, No. ICAS (n ¼ 344), No. (%)c Controls (n ¼ 589), No. (%)c OR (95% CI)a Pb
0 224 54 (24.1) 170 (75.9) Referent Referent
1 357 105 (29.4) 252 (70.6) 1.1 (1.0-0.4) .145
2 217 86 (39.6) 131 (60.4) 1.6 (1.2-3.2) <.001
3 83 54 (65.1) 29 (34.9) 2.6 (1.5-5.9) <.001
4 39 32 (82.1) 7 (17.9) 6.8 (2.1-26.3) <.001
$5 13 13 (100) 0 e <.001
CI, Conﬁdence interval; HRGs, high-risk genotypes; OR, odds ratio.
aORs adjusted for age, sex, presence of hypertension, hypercholesterolemia, diabetes, coronary artery disease, peripheral arterial occlusive disease, history of
ischemic stroke, and smoking.
bP values were assessed by Fisher exact test for categoric value.
cNumbers in parentheses are percentages of total.
Table V. Genotype distribution patients with stable
plaque (SP) and without unstable plaque (USP)
Genotypes
USP (n ¼ 156),
No. (%)b
SP (n ¼ 188),
No. (%)b Pa
IL-6
GG 80 (51.3) 52 (27.7) <.001
GC 57 (36.5) 98 (52.1)
CC 19 (12.2) 38 (20.2)
IL-1b
TT 33 (21.2) 10 (5.3) <.001
CT 69 (44.2) 85 (45.2)
CC 54 (34.6) 93 (49.5)
CCL2
GG 54 (34.6) 23 (12.2) <.001
AG 68 (43.6) 85 (45.2)
AA 34 (21.8) 80 (42.6)
CCL3
66 96 (61.5) 67 (35.6) <.001
64 51 (32.7) 96 (51.1)
44 9 (5.8) 25 (13.3)
SELE
AA 12 (7.7) 5 (2.7) .002
AS 63 (40.4) 74 (39.3)
SS 81 (51.9) 109 (58.0)
ICAM-1
EE 55 (35.3) 25 (13.3) <.001
EK 84 (53.8) 103 (54.8)
KK 17 (10.9) 60 (31.9)
MMP-3
5A5A 65 (41.7) 19 (10.1) <.001
6A5A 79 (50.6) 92 (48.9)
6A6A 12 (7.7) 77 (41.0)
MMP-9
TT 12 (7.7) 3 (1.6) .02
CT 49 (31.4) 53 (28.2)
CC 95 (60.9) 132 (70.2)
CCL2, Monocyte chemoattractant protein-1; CCL3, macrophage inﬂam-
matory protein-1a; ICAM-1, intercellular adhesion molecule-1; IL, inter-
leukin; MMP, matrix metalloproteinase; SELE, E-selectin.
aP values assessed by Fisher exact test for categoric value.
bNumbers in parentheses are percentages of total.
Table VI. Logistic regression analysis
Genotypes OR (95% CI)a
IL-6/GG 2.6 (1.5-3.9)
IL-1b/TT 3.5 (1.4-7.1)
CCL2/GG 3.1 (1.6-5.7)
CCL3/66 2.8 (1.6-4.1)
SELE/AA 2.7 (1.4-6.9)
ICAM-1/EE 3.9 (2.1-5.9)
MMP-3/5A5A 5.2 (2.6-9.9)
MMP-9/TT 3.2 (1.3-6.2)
CCL2, Monocyte chemoattractant protein-1; CCL3, macrophage inﬂam-
matory protein-1a; CI, conﬁdence interval; ICAM-1, intercellular adhesion
molecule-1; IL, interleukin; MMP, matrix metalloproteinase; OR, odds ra-
tio; SELE, E-selectin.
aORs adjusted for age, sex, presence of hypertension, hypercholesterolemia,
diabetes, coronary artery disease; peripheral arterial occlusive disease; history
of ischemic stroke, and smoking.
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>3, >2, >2, >3, >5, and >3 times higher, respectively,
of developing unstable carotid plaque, as reported in
Table VI.Finally, our study evaluated whether the combined
effects of these gene polymorphisms increased the risk for
USP. We found that the OR for USP, calculated after
adjusting for the same variables, increased progressively
according to the number of HRGs: the risk of USP was
6.6 (95% CI, 2.3-20.2) in the group with 1 HRG, 18.4
(95% CI, 4.8-66.4) in individuals with 2 HRGs, 71.2
(95% CI 9.6-397.8) in individuals with 3 HRGs, and
489.5 (95 CI 12.9-1865.3) in individuals with 4 HRGs.
The 13 individuals with ﬁve or more HRGs showed USP
(Table VII).
DISCUSSION
The results of our study show, for the ﬁrst time, that the
IL-6, IL-1b, CCL2, CCL3, SELE, ICAM-1, MMP-3, and
MMP-9 gene polymorphisms are associated with ICAS.
Furthermore, we found that the combination of these proin-
ﬂammatory genes determines an increased of risk for unsta-
ble atherosclerotic plaque in individuals with ICAS.
Interestingly, the risk level depends on the HRG type and
number simultaneously carried by the patient.
In particular, we found that the ICASpatients had signif-
icantly higher frequencies than control patients of the IL-6
Table VII. Risk for unstable plaque (USP) according to the number of proinﬂammatory gene polymorphisms
HRGs, No. Patients, No. USP (n ¼ 156), No. (%)c SP (n ¼ 188), No. (%)c OR (95% CI)a Pb
0 54 6 (11.1) 48 (88.9) Referent Referent
1 105 39 (37.1) 66 (62.9) 6.6 (2.3-20.2) <.001
2 86 42 (48.9) 44 (51.1) 18.4 (4.8-66.4) <.001
3 54 33 (61.1) 22 (38.9) 71.2 (9.6-397.8) <.001
4 32 23 (71.9) 9 (28.1) 489.5 (12.9-1865.3) <.001
$5 13 13 (100) 0 e <.001
CI, Conﬁdence interval; HRGs, high-risk genes; OR, odds ratio; SP, stable plaque.
aORs adjusted for age, sex, presence of hypertension, hypercholesterolemia, diabetes, coronary artery disease, peripheral arterial occlusive disease, history of
ischemic stroke, and smoking.
bP values were assessed by Fisher exact test for categoric values.
cNumbers in parentheses are percentages of the total.
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.006), CCL2 (22.4% vs 8.5%; P < .001), CCL3 (47.4% vs
39.0%; P < .001), SELE (4.9% vs 1.4%; P < .001), ICAM-
1 (24.1% vs 11.9%; P < .001), MMP-3 (24.7% vs 14.4%;
P < .001), and MMP-9 (4.4 vs 1.2%; P ¼ .008) genes
(Table II). In our population, the occurrence of ICAS was
3.1 times, 2.0 times, 3.9 times, 2.1 times, 5.1 times, 3.7
times, 2.5 times, and 3.9 times more common in individuals
homozygous for the G, T, G, 6, A, E, 5A5A, and T alleles of
the IL-6, IL-1b, CCL2, CCL3, SELE, ICAM-1, MMP-3,
and MMP-9 gene polymorphisms compared with the other
individuals (Table III). One of the most signiﬁcant discov-
eries of this study is that it can deﬁne a potential genetic pro-
ﬁle in which multiple gene polymorphisms can act
simultaneously in patients with ICAS. In particular, with
an augmented number of proinﬂammatory HRGs, the risk
for ICAS increased gradually and was 1.6, 2.6, and 6.8 in
the carotid arteries of individuals with 2, 3, or 4 HRGs,
respectively. All patients with ﬁve or more HRGs had
ICAS (Table IV).
Importantly, when we grouped the patients by USP
and SP, patients homozygous for the same genotypes had
a risk of developing an USP that was 2.6 times, 3.5 times,
3.1 times, 2.8 times, 2.7 times, 3.9 times, 5.2 times, and
3.2 times higher for developing USP (Table VI).
The goal of this study was to show that an increasing
number of proinﬂammatory HRGs in individuals with
ICAS increased the risk of developing USP, which was
calculated at 6.6 times, 18.4 times, 71.2 times, and 489.5
times in patients with 1, 2, 3, or 4 HRGs (Table V). The
13 patients with ﬁve or more HRGs had USP (Table VII).
The gene mutations investigated in this study are func-
tionally important, and this is why they have a relevant bio-
logical signiﬁcance in the observed associations. In fact, the
IL-6 gene polymorphism modulates the gene transcription
rate and controls IL-6 systemic levels.30 Likewise, CCL2
gene expression is modulated by the CCL2 gene polymor-
phism.31 Furthermore, the amino acid sequence of the
immunoglobulin-like domain 5 is dependent on the
ICAM-1469 E/K gene polymorphism and it is very relevant
for the B-cell adhesion and for lymphocyte function-
associated antigen-1/ICAM-1 interactions.32 Clearly,
crucial clinical consequences derive from these relevantbiologic effects, as suggested by the control that these gene
polymorphisms may apply on the beginning and disease
severity of several pathologies, such as ICAS.
Atherosclerosis is a chronic inﬂammatory condition.
Atherosclerotic plaque destabilization and rupture and suc-
cessive clinical complications depend on several inﬂammatory
molecules involved in the atherosclerosis pathogenesis. A pro-
thrombotic condition is induced by IL-6, and this cytokine
plays an important direct atherogenic role in addition to
its acute-phase response-initiating and its inﬂammatory
cascade-amplifying function.33
In experimental models, the atherosclerosis extent and
macrophage inﬁltration into the atherosclerotic lesion was
directly related to CCL2 expression, and antimonocyte
CCL2 gene therapy in apolipoprotein E-knockout mice
reduced the atherosclerosis progression and destabiliza-
tion.34 MMPs show a crucial role in plaque vulnerability:
MMPs are highly represented in macrophage-rich areas of
atherosclerotic plaque, in particular in the cap shoulder
region, which might initiate ﬁbrous cap impairment and
atherosclerotic lesions destabilization.35 Measurement
of SELE seems useful for detecting coronary plaque
destabilization.36
According toour data, wemight conﬁrm the concept that
an individual’s tendency to develop inﬂammation-dependent
disease might be related to a susceptibility proﬁle based on
functional interactions among a number of different genes.
Indeed, several other pathologic conditions, such as ischemic
stroke,37 atrophic gastritis,13 and rheumatoid arthritis,15 have
been related to the additive effects among inﬂammatory gene
variations.
We found that the risk of unstable carotid plaque is higher
when the number of inﬂammation-promoting genotypes in a
single patient is increased, suggesting that the studied gene
mutations might act in a cumulative and synergistic way. It
is also important to underline that the relevant physiologic in-
teractions displayed by their corresponding proteins reﬂect
the cooperative and interdependent effects of these gene var-
iations. Moreover, the CCL2 protein stimulates IL-6 secre-
tion and ICAM-1 synthesis in a time-and dose-dependent
mechanism.
This study has important limitations. First, it is a case-
control study; thus, recruitment and survival bias cannot be
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European descent cohort that included patients with other
potentially relevant pathologic conditions, and so comor-
bidity might represent a inﬂuencing factor. The population
size included in the study is relatively small, and our data
need to be conﬁrmed in larger evaluations and should be
analyzed in different ethnic groups. Some of the investi-
gated genes present more than one SNP, and it might be
important to analyze whether proinﬂammatory genetic
haplotypes play a role in individuals with carotid plaque.
CONCLUSIONS
This study demonstrates that variations in genes encod-
ing for typical inﬂammatory molecules, such as IL-6,
IL-1b, CCL2, CCL3, SELE, ICAM-1, MMP-3, and
MMP-9, are independently and signiﬁcantly associated
with ICAS and that they can deﬁne a potential genetic pro-
ﬁle in which multiple gene polymorphisms act synergisti-
cally in patients with USP. Further studies are needed to
conﬁrm these results, and additional experiments are essen-
tial to assess the relative effect of these inﬂammatory
markers on the progression of ICAS and to establish
whether these associations are of causal relevance.
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